Posted by Michael Wonder on 29 May 2026
BeOne Medicines receives positive reimbursement recommendations from CDA-AMC and INESSS for Tevimbra in first-line nasopharyngeal carcinoma
28 May 2026 - BeOne Medicines today announced that Canada's Drug Agency and the Institut national d'excellence en santé et en services sociaux, issued positive reimbursement recommendations for Tevimbra (tislelizumab for injection) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma.
These recommendations follow Health Canada's approval of Tevimbra in December 2025 for this indication and represent an important step toward access for patients, as there is currently no publicly funded first-line immunotherapy option for recurrent or metastatic nasopharyngeal carcinoma in Canada.
